These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 7535978)

  • 1. Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer.
    Figg WD; Sartor O; Cooper MR; Thibault A; Bergan RC; Dawson N; Reed E; Myers CE
    Am J Med; 1995 Apr; 98(4):412-4. PubMed ID: 7535978
    [No Abstract]   [Full Text] [Related]  

  • 2. Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade.
    Schellhammer PF; Venner P; Haas GP; Small EJ; Nieh PT; Seabaugh DR; Patterson AL; Klein E; Wajsman Z; Furr B; Chen Y; Kolvenbag GJ
    J Urol; 1997 May; 157(5):1731-5. PubMed ID: 9112515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of patients with androgen-independent prostatic carcinoma whose serum prostate specific antigen decreased following flutamide withdrawal.
    Herrada J; Dieringer P; Logothetis CJ
    J Urol; 1996 Feb; 155(2):620-3. PubMed ID: 8558675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination finasteride and flutamide in advanced carcinoma of the prostate: effective therapy with minimal side effects.
    Fleshner NE; Trachtenberg J
    J Urol; 1995 Nov; 154(5):1642-5; discussion 1645-6. PubMed ID: 7563310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
    Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
    J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study.
    Sato N; Akakura K; Isaka S; Nakatsu H; Tanaka M; Ito H; Masai M;
    Urology; 2004 Aug; 64(2):341-5. PubMed ID: 15302491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Primary treatment for stage D2 prostate cancer: a randomized study of combined androgen blockade alone versus combined with UFT].
    Sumiyoshi Y; Hashine K; Kuwahara M; Aki M; Yamamoto A; Akazawa S; Takenaka A
    Gan To Kagaku Ryoho; 1999 Jul; 26(8):1153-8. PubMed ID: 10431581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: a pilot study.
    Higano CS; Ellis W; Russell K; Lange PH
    Urology; 1996 Nov; 48(5):800-4. PubMed ID: 8911533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The change in the dihydrotestosterone level in the prostate before and after androgen deprivation therapy in connection with prostate cancer aggressiveness using the Gleason score.
    Nishiyama T; Ikarashi T; Hashimoto Y; Wako K; Takahashi K
    J Urol; 2007 Oct; 178(4 Pt 1):1282-8; discussion 1288-9. PubMed ID: 17698092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cryosurgery of prostate cancer. Use of adjuvant hormonal therapy and temperature monitoring--A one year follow-up.
    Lee F; Bahn DK; McHugh TA; Kumar AA; Badalament RA
    Anticancer Res; 1997; 17(3A):1511-5. PubMed ID: 9179188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Change of the cell cycle after flutamide treatment in prostate cancer cells and its molecular mechanism.
    Wang Y; Shao C; Shi CH; Zhang L; Yue HH; Wang PF; Yang B; Zhang YT; Liu F; Qin WJ; Wang H; Shao GX
    Asian J Androl; 2005 Dec; 7(4):375-80. PubMed ID: 16281084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases.
    Koutsilieris M; Mitsiades CS; Bogdanos J; Dimopoulos T; Karamanolakis D; Milathianakis C; Tsintavis A
    Clin Cancer Res; 2004 Jul; 10(13):4398-405. PubMed ID: 15240528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of short-term finasteride on apoptotic factors and androgen receptors in prostate cancer cells.
    Bass R; Perry B; Langenstroer P; Thrasher JB; Dennis KL; Tawfik O; Holzbeierlein J
    J Urol; 2009 Feb; 181(2):615-9; discussion 619-20. PubMed ID: 19091346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of flutamide as a second-line agent for maximum androgen blockade of hormone refractory prostate cancer.
    Nishimura K; Arichi N; Tokugawa S; Yoshioka I; Kishikawa H; Ichikawa Y
    Int J Urol; 2007 Mar; 14(3):264-7. PubMed ID: 17430272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized phase II trial of flutamide vs chlormadinone acetate in previously untreated advanced prostatic cancer. The Japan Flutamide Study Group.
    Akaza H; Usami M; Kotake T; Koiso K; Aso Y
    Jpn J Clin Oncol; 1993 Jun; 23(3):178-85. PubMed ID: 7688829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of mutant androgen receptors by flutamide.
    Ishioka J; Hara S; Isaacs JT; Tomura A; Nishikawa K; Kageyama Y
    Int J Urol; 2009 May; 16(5):516-21. PubMed ID: 19389135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphorylation/dephosphorylation of androgen receptor as a determinant of androgen agonistic or antagonistic activity.
    Wang LG; Liu XM; Kreis W; Budman DR
    Biochem Biophys Res Commun; 1999 May; 259(1):21-8. PubMed ID: 10334909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant hormone therapy and radical radiotherapy for localized prostate cancer: poorer biochemical outcome using flutamide alone.
    Wilson KS; Ludgate CM; Wilson AG; Alexander AS
    Can J Urol; 2000 Oct; 7(5):1099-103. PubMed ID: 11114872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
    Okegawa T; Nutahara K; Higashihara E
    J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The effects of LH-RH agonist alone or with flutamide in the treatment of stage D2 prostate cancer].
    Ito T; Aizawa T; Yamamoto S; Ohkubo Y; Tsujino S; Miki M
    Hinyokika Kiyo; 1998 Jul; 44(7):477-80. PubMed ID: 9752601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.